EUVIMEDScopri EUVIMED
MetaanalyseSystematische ÜbersichtOpen access · CC BY-NC 4.0

MS Fatigue Post High‐Efficacy Treatment

C Sales iD, R Patel, T Wijeratne iD, A Bruestle iD, N Cherbuin iD

European Journal of Neurology · 2025

DOI: 10.1111/ene.70385 ↗

At a glance

Metaanalyse in European Journal of Neurology, 2025. Written by C Sales and 4 co-authors. Institution: ANU College of Law, Governance and Policy, Australian National University, Canberra, Australia. Major MEDLINE topics: Fatigue, Multiple Sclerosis, Relapsing-Remitting, Multiple Sclerosis. Cited 1 times so far (Crossref); 48 references. The full text is freely available (open access, CC BY-NC 4.0).

AbstractSubjectsDati bibliograficiCiteRelated studies

Abstract (original language)

Background

Multiple sclerosis (MS) is a major cause of disability, particularly among young adults, with fatigue affecting up to 95% of patients. Despite the availability of disease‐modifying therapies (DMTs), their impact on MS‐related fatigue (MSF) remains uncertain. This study investigates changes in fatigue levels among individuals with relapsing–remitting MS (RRMS) following the initiation of highly effective therapies (HETs).

Methods

A systematic search of MEDLINE, PubMed, Scopus, and PsycINFO identified studies involving adults with RRMS treated with HETs and assessed using validated fatigue measures at baseline and follow‐up. Data on demographics, MS duration, DMT type, and fatigue scores were extracted. Meta‐analyses using a random‐effects model calculated standardized mean differences (SMD) in fatigue scores post‐treatment.

Results

Eighteen studies comprising 4138 RRMS patients and 3806 person‐years of follow‐up were included. The overall SMD was −0.34 (95% CI −0.47 to −0.21), indicating a small but significant reduction in fatigue. Continuous treatments (e.g., natalizumab, ocrelizumab, fingolimod) showed significant improvements, while immune reconstituting therapies (e.g., alemtuzumab) did not. Among fatigue domains, only physical fatigue showed a significant reduction, particularly with natalizumab (SMD = −1.25; 95% CI −2.43 to −0.06) and when assessed using the fatigue scale for motor and cognitive functions scale (SMD = −1.52; 95% CI −2.87 to −0.17).

Conclusion

MS‐related fatigue levels, especially in its physical aspect, decrease after the initiation of HET. This finding reinforced the role of neuroinflammation in driving fatigue and highlighted the need for domain‐specific research and treatment strategies.

Subjects

MeSH terms (MEDLINE)

FatigueMultiple Sclerosis, Relapsing-RemittingMultiple SclerosisHumansTreatment Outcome

Author keywords

fatiguehighly effective DMTsmultiple sclerosispatient‐reported outcomesrelapsing–remitting

Authors and institutions

  • ANU College of Law, Governance and Policy, Australian National University, Canberra, Australia.
  • Department of Neurology, The North Canberra Hospital, Canberra, Australia.
  • Department of Neurology & Stroke Services, Western Health, Melbourne, Australia.
  • John Curtin School of Medical Research, Australian National University, Canberra, Australia.

ORCID profiles: C Sales, T Wijeratne, A Bruestle, N Cherbuin

Cite

APA

Sales, C., Patel, R., Wijeratne, T., Bruestle, A., & Cherbuin, N. (2025). MS Fatigue Post High‐Efficacy Treatment. European Journal of Neurology. https://doi.org/10.1111/ene.70385

Vancouver

Sales C, Patel R, Wijeratne T, Bruestle A, Cherbuin N. MS Fatigue Post High‐Efficacy Treatment. European Journal of Neurology. 2025. doi:10.1111/ene.70385

BibTeX
@article{Sales2025,
  author = {Sales, C and Patel, R and Wijeratne, T and Bruestle, A and Cherbuin, N},
  title = {MS Fatigue Post High‐Efficacy Treatment},
  journal = {European Journal of Neurology},
  year = {2025},
  doi = {10.1111/ene.70385}
}
Start for free →